The PE Ratio as of November 2024 (TTM) for Novo Nordisk A/S (NONOF) is 38.13

According to Novo Nordisk A/S’s latest financial reports and current stock price. The company's current PE Ratio is 38.13. This represents a change of -5.82% compared to the average of 40.48 of the last 4 quarters.

Novo Nordisk A/S (NONOF) Historical PE Ratio (quarterly & annually)

How has NONOF PE Ratio performed in the past?

The mean historical PE Ratio of Novo Nordisk A/S over the last ten years is 21.47. The current 38.13 PE Ratio has changed 17.66% with respect to the historical average. Over the past ten years (40 quarters), NONOF's PE Ratio was at its highest in in the June 2024 quarter at 55.42. The PE Ratio was at its lowest in in the March 2017 quarter at 7.47.

Novo Nordisk A/S (NONOF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Novo Nordisk A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Novo Nordisk A/S (NONOF) Average PE Ratio

How has NONOF PE Ratio performed in the past?

The current PE Ratio of Novo Nordisk A/S (NONOF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Novo Nordisk A/S (NONOF) PE Ratio vs. Peers

How is NONOF’s PE Ratio compared to its peers?

Novo Nordisk A/S’s PE Ratio is greater than Nuvalent, Inc. (-33.32), greater than DICE Therapeutics, Inc. (-23.17), greater than Arcellx, Inc. (-85.84), greater than Vaxcyte, Inc. (-25.11), greater than Viridian Therapeutics, Inc. (-6.40), greater than CSL Limited (19.22), greater than BeiGene, Ltd. (-41.43), greater than Acelyrin, Inc. (-1.93), greater than Caribou Biosciences, Inc. (-1.71), less than CSL Limited (0), greater than PMV Pharmaceuticals, Inc. (23.61), greater than KalVista Pharmaceuticals, Inc. (-1.73), greater than ProKidney Corp. (-3.79), greater than EPIRUS Biopharmaceuticals, Inc. (-2.02), less than NovAccess Global Inc. (0), greater than ImmunoCellular Therapeutics, Ltd. (-0.21), greater than VG Life Sciences Inc. (0), greater than Genenta Science S.p.A. (-20.33), greater than null (-0.01),

Build a custom stock screener for Novo Nordisk A/S (NONOF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novo Nordisk A/S using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Novo Nordisk A/S (NONOF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Novo Nordisk A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.